North Carolina life sciences companies, startups and academic institutions are tackling some of the world's greatest ...
New licensing Guidelines issued by the National Institutes of Health at the end of the Biden Administration could harm ...
This is common. Those of us in research routinely store patient samples — blood, fluids, tissue, scrapings, and other ...
The Plant and Animal Genomics conference recently held in San Diego showcased the ways that rapidly advancing technologies can be used in the crop and livestock sectors ...
Babson Diagnostics, a science-first healthcare technology company, today announced that BetterWay™ blood testing is a ...
After months of leaks and rumors, the Galaxy S25 Series is finally official! Samsung’s latest flagship devices were announced during the Winter Unpacked event on January 22, and while there weren’t ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback